{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:52:49Z","timestamp":1772236369685,"version":"3.50.1"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,7]]},"DOI":"10.18632\/oncotarget.14181","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T14:26:48Z","timestamp":1482848808000},"page":"9647-9659","source":"Crossref","is-referenced-by-count":16,"title":["Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis"],"prefix":"10.18632","volume":"8","author":[{"given":"Katarina","family":"Lyberg","sequence":"first","affiliation":[{"name":"Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and clinical immunology and transfusion medicine, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani Abdulkadir","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet and Hematology Center, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennine","family":"Grootens","sequence":"additional","affiliation":[{"name":"Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and clinical immunology and transfusion medicine, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilda","family":"Kjellander","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet and Hematology Center, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Tirfing","sequence":"additional","affiliation":[{"name":"Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and clinical immunology and transfusion medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Oncology, LBPA CNRS UMR 8113, Ecole Normale Sup\u00e9rieure de Cachan, Cachan, France and Laboratoire Central d\u2019H\u00e9matologie, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"H\u00e4gglund","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and clinical immunology and transfusion medicine, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Ungerstedt","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet and Hematology Center, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Vardiman","year":"2016","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am J Hematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Cells, Mastocytosis, and Related Disorders","volume":"373","author":"Mast","year":"2015","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: status in 2015 and future perspectives","volume":"94","author":"Valent","year":"2015","journal-title":"Eur J Haematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: an emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"6","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis","volume":"22","author":"Kota","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood-2004-12-4792","article-title":"Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim","volume":"106","author":"Nilsson","year":"2005","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Metcalfe","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Ashman","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Besnard","year":"2016","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Valent","year":"2016","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2013.092007","article-title":"Epigenetics in the hematologic malignancies","volume":"99","author":"Dawson","year":"2014","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/leu.2013.343","article-title":"Epigenetics of myelodysplastic syndromes","volume":"28","author":"Fenaux","year":"2014","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Levine","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Ernst","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2014.03.013","article-title":"Molecular basis of mast cell disease","volume":"63","author":"Dubreuil","year":"2015","journal-title":"Mol Immunol"},{"key":"18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Soucie","year":"2014","journal-title":"Haematologica"},{"key":"19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Cross","year":"2016","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Reiter","year":"2015","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Dubreuil","year":"2012","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"Johnstone","year":"2014","journal-title":"J Clin Invest"},{"key":"23","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bhalla","year":"2005","journal-title":"J Biol Chem"},{"key":"24","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1158\/0008-5472.CAN-08-4004","article-title":"Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors","volume":"69","author":"Bauer","year":"2009","journal-title":"Cancer Res"},{"key":"25","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Davidsen","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"26","first-page":"773","article-title":"Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines","volume":"24","author":"Teh","year":"2004","journal-title":"Int J Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.0408345102","article-title":"Apoptotic and autophagic cell death induced by histone deacetylase inhibitors","volume":"101","author":"Jiang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2009-07-231985","article-title":"AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit","volume":"115","author":"London","year":"2010","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4161\/epi.23752","article-title":"Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients","volume":"8","author":"Hermanson","year":"2013","journal-title":"Epigenetics"},{"key":"30","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Marks","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.path.2015.05.006","article-title":"Genetics of Gastrointestinal Stromal Tumors: A Heterogeneous Family of Tumors?","volume":"8","author":"Rubin","year":"2015","journal-title":"Surg Pathol Clin"},{"key":"32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ijc.24048","article-title":"Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas","volume":"124","author":"Saida","year":"2009","journal-title":"Int J Cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature07829","article-title":"Histone modifications at human enhancers reflect global cell-type-specific gene expression","volume":"459","author":"Lobanenkov","year":"2009","journal-title":"Nature"},{"key":"34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","article-title":"Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene","volume":"108","author":"Nilsson","year":"2003","journal-title":"Immunology"},{"key":"35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Dubreuil","year":"2014","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.5RU0614-296R","article-title":"The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis","volume":"97","author":"Orfao","year":"2015","journal-title":"J Leukoc Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T12:10:50Z","timestamp":1589112650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,25]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,7]]}},"alternative-id":["14181","28038453"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14181","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727153866.793539105","asserted-by":"object"}]},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,25]]}}}